Lung cancer in the elderly: Current and future chemotherapeutic options

Drugs and Aging

Volumn 19, Issue 5, 2002, Pages 365-375

  Hinton, Stuart ^a   Sandler, Alan ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MITOMYCIN; NAVELBINE; PACLITAXEL; PLATINUM; SEMUSTINE; VINDESINE;

AGED; AGING; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW;

EID: 0036074185     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200219050-00005     Document Type: Review

References (44)

1. Cancer statistics, 1999
2. Cancer burden in the aged: An epidemiologic and demographic overview
3. Prediction of creatinine clearance from serum creatinine
4. Lack of age-dependent cisplatin nephrotoxicity
5. Renal tolerance of cisplatin in patients more than 80 years old
6. Use of cisplatin for elderly patients
7. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
8. Age and cytochrome P450-linked drug metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions
9. Geriatric principles of treatment applied to medical oncology: An overview
10. Hematopoiesis in the aged: A model of hematopoietic dysregulation?
11. Age-related declines in hematopoietic reserve capacity
12. Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group
13. Advanced age alone does not compromise outcome in fit Non-Small Cell Lung Cancer (NSCLC) patients (pts) receiving platinum (DDP)-based therapy (TX): Implications of ECOG 5592
14. Risk factors for doxorubicin-induced congestive heart failure
15. Age dependence of the early-phase pharmacokinetics of doxorubicin
16. Psychosocial consequences of cancer chemotherapy for elderly patients
17. Representation of older patients in cancer treatment trials
18. Underrepresentation of patients 65 years of age or older in cancer-treatment trials
19. Long-term survivors in metastatic non-small-cell lung cancer: An Eastern Cooperative Oncology Group Study
20. Prognostic factors in advanced Non-Small Cell Lung Cancer (NSCLC): Analysis of Eastern Cooperative Oncology Group (ECOG) trials from 1981-1992
21. Chemotherapy for non-small cell lung cancer: Have we reached a new plateau?
22. Efficacy study of intensive cis-platin therapy in advanced non-small cell bronchogenic carcinoma
23. Mitomycin C in advanced adenocarcinoma and large cell carcinoma of the lung
24. Vindesine: An effective agent in the treatment of non-small cell lung cancer
25. Single-dose ifosfamide: Efficacy studies in non-small cell lung cancer
26. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group
27. Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients
28. Weekly vinorelbine in elderly patients with non-small-cell lung cancer
29. Gemcitabine in the treatment of elderly patients with advanced non- small cell lung cancer
30. Chemotherapy (CT) with Cisplatin and Vinorelbine for elderly Non-Small Cell Lung Cancer (NSCLC)
31. Advancing age does not exacerbate toxicity or compromise outcome in Non-Small Cell Lung Cancer (NSCLC) patients (pts) receiving Paclitaxel-Carboplatin (P-C)
32. Cisplatin-based combination chemotherapy for elderly patients with non- small-cell lung cancer
33. The safety and efficacy of Gemcitabine plus Cisplatin in the elderly chemonaive NSCLC patients (age>70 years) as compared to those with age<70 years
34. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer
35. Gemcitabine + Vinorelbine (GV) yields better survival than Vinorelbine (V) alone in elderly Non-Small Cell Lung Cancer (NSCLC) patients. Final analysis of a Southern Italy Cooperative Group (S1COG) phase 111 trial
36. Treatment of small cell lung carcinoma in the elderly
37. Chemotherapy in elderly patients with Small Cell Lung Cancer (SCLC)
38. A phase 11 study of oral etoposide in elderly patients with small cell lung cancer
39. Single-agent oral etoposide for elderly small cell lung cancer patients
40. Oral etoposide and carboplatin. Effective therapy for elderly patients with small cell lung cancer
41. Five day oral etoposide treatment for advanced small-cell lung cancer: Randomized comparison with intravenous chemotherapy
42. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multicentre randomised trial
43. A Comprehensive Geriatric Assessment (CGA) is necessary for the study and the management of cancer in the elderly
44. Scales to measure competence in everyday activities